The episode highlights a growing tension between federal and state authorities. As federal agencies like the FDA appear to relax enforcement on products like e-cigarettes or face legal challenges to their authority over drugs like mifepristone, states are increasingly stepping in with their own stricter regulations and legal actions.
The discussion explores the conflict between protecting public health and promoting commercial interests or individual liberty. The FDA's relaxed stance on e-cigarettes is framed as a win for the tobacco industry and a move away from "nanny state" policies, despite known public health risks like youth addiction.
The episode examines a legal crackdown on deceptive digital marketing, specifically the use of "false urgency" in promotional emails. A Washington state law is being leveraged in over 100 lawsuits against retailers for misleading consumers with time-sensitive offers that are later extended or repeated.
The episode illustrates how regulatory bodies like the FDA are subject to significant political pressure, which can influence enforcement priorities and scientific review processes. Decisions regarding e-cigarettes and mifepristone are presented not just as scientific matters, but as outcomes of political maneuvering and administration priorities.
Keep pulling the thread on Bloomberg Law.